ARUXF Stock Chart & Stats
$0.02
$0.00(0.00%)
At close: 4:00 PM EDT
$0.02
$0.00(0.00%)
Day’s Range― - ―
52-Week Range<$0.01 - $0.05
Previous CloseN/A
Volume55.00
Average Volume (3M)0.00
Market Cap
$4.30M
Enterprise Value$5.85M
Total Cash (Recent Filing)$1.71M
Total Debt (Recent Filing)$2.52M
Price to Earnings (P/E)―
Beta0.91
Next Earnings
Mar 02, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield12.35%
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding612,154,100
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)3.46
Price to Sales (P/S)1.09
P/FCF Ratio4.98
Enterprise Value/Market Cap1.36
Enterprise Value/Revenue1.26
Enterprise Value/Gross Profit1.39
Enterprise Value/Ebitda-3.44
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)<0.01
Revenue Forecast (FY)$9.96M
Bulls Say, Bears Say
Bulls Say
2026 Revenue ReboundThe strong 2026 revenue rebound indicates renewed commercial traction after two difficult years. If revenue can remain at this higher base, it would improve operating leverage, support investment in the biotechnology portfolio, and provide a foundation for future earnings recovery.
Positive Recent Cash FlowPositive operating and free cash flow in the latest year is an important improvement because it reduces immediate reliance on external funding. Sustained cash generation would strengthen financial resilience and give management more flexibility to support development and commercial priorities.
Narrowing Net LossA sharply narrower net loss shows that the recent revenue recovery is translating into improved financial performance, even though profitability has not yet been achieved. Continued progress could reduce cash requirements and move the company closer to sustainable earnings over time.
Bears Say
Persistent UnprofitabilityPersistent net, EBIT, and EBITDA losses indicate that the business has not yet demonstrated a sustainable profit model. Until operating earnings become positive, cash generation may remain vulnerable and the company may have less capacity to fund growth without balance-sheet support.
Highly Volatile RevenueLarge year-to-year revenue swings make the company’s earnings power difficult to establish and increase the risk that recent improvement may not persist. This volatility can complicate planning, weaken operating leverage, and make future cash generation less predictable.
Weakened Balance SheetA compressed equity base and elevated debt-to-equity ratio leave less protection for creditors and shareholders, particularly while losses continue. Declining assets also suggest reduced financial flexibility, potentially limiting the company’s ability to absorb setbacks or fund development internally.
Acrux News
ARUXF FAQ
What was Acrux Limited’s price range in the past 12 months?
Acrux Limited lowest stock price was <$0.01 and its highest was $0.05 in the past 12 months.
What is Acrux Limited’s market cap?
Acrux Limited’s market cap is $4.30M.
When is Acrux Limited’s upcoming earnings report date?
Acrux Limited’s upcoming earnings report date is Mar 02, 2027 which is in 126 days.
How were Acrux Limited’s earnings last quarter?
Acrux Limited released its earnings results on Aug 21, 2026. The company reported -$0.001 earnings per share for the quarter.
Is Acrux Limited overvalued?
According to Wall Street analysts Acrux Limited’s price is currently Overvalued.
Does Acrux Limited pay dividends?
Acrux Limited pays a Annually dividend of $0.063 which represents an annual dividend yield of 12.35%. See more information on Acrux Limited dividends here
What is Acrux Limited’s EPS estimate?
Acrux Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Acrux Limited have?
Acrux Limited has 612,154,100 shares outstanding.
What happened to Acrux Limited’s price movement after its last earnings report?
Acrux Limited reported an EPS of -$0.001 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Acrux Limited?
Currently, no hedge funds are holding shares in ARUXF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Acrux Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Neutral
ARUXF Sentiment 50%
Sector Average 67%
Sector Average 67%
Insider Transactions
Bought Shares
Worth $105.0K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Fundamentals
Return on Equity
-45.29%
Trailing 12-Months
Asset Growth
-12.39%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Acrux Limited
Acrux Limited and its associated entities specialize in the development and commercialization of generic and topically applied pharmaceutical products. Their global operations span Australia, Europe, the United States, and various other international markets. The company provides a comprehensive range of testosterone therapies for adult males experiencing insufficient or absent testosterone levels, including oral and buccal tablets, subcutaneous pellets, transdermal patches, injectable formulations, and topical gels. Furthermore, Acrux offers estradiol sprays, specifically marketed under the brand names Evamist and Lenzetto, to women for the management of hot flashes associated with menopause. Established in 1998, the firm's headquarters are located in West Melbourne, Australia.
Technical Analysis
Clinuvel Pharmaceuticals
―
Starpharma Holdings Limited
―
Tissue Repair Ltd
―
Regeneus Ltd.
―
Botanix Pharmaceuticals Limited
―